HC Wainwright Predicts Altimmune’s Q2 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) – Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Altimmune in a research report issued to clients and investors on Monday, May 18th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.14) per share for the quarter, up from their prior forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Altimmune’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.63) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.22) EPS and FY2027 earnings at ($0.80) EPS.

Several other brokerages also recently weighed in on ALT. Citizens Jmp reduced their price target on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. Truist Financial initiated coverage on Altimmune in a research note on Wednesday, March 18th. They set a “buy” rating and a $12.00 target price on the stock. Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Barclays assumed coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price for the company. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.67.

Altimmune Price Performance

ALT opened at $2.74 on Wednesday. Altimmune has a 12-month low of $2.56 and a 12-month high of $7.73. The company has a current ratio of 29.56, a quick ratio of 29.56 and a debt-to-equity ratio of 0.12. The stock has a fifty day simple moving average of $3.23 and a two-hundred day simple moving average of $4.08. The company has a market cap of $356.47 million, a price-to-earnings ratio of -2.95 and a beta of 0.18.

Altimmune (NASDAQ:ALT) last announced its earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Arax Advisory Partners increased its position in Altimmune by 99.7% during the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares in the last quarter. SBI Securities Co. Ltd. grew its stake in Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in shares of Altimmune in the first quarter worth about $33,000. Quadrature Capital Ltd purchased a new stake in shares of Altimmune in the fourth quarter worth about $36,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Altimmune in the third quarter worth about $38,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Altimmune

In related news, CEO Jerome Benedict Durso purchased 20,000 shares of Altimmune stock in a transaction dated Friday, March 6th. The stock was purchased at an average cost of $3.54 per share, with a total value of $70,800.00. Following the transaction, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.